Over the last 25 years, significant improvements in overall survival have been achieved in MM management, largely due to the incorporation of agents such as proteasome inhibitors (bortezomib, carfilzomib, ixazomib), immunomodulatory drugs (thalidomide, lenalidomide, pomalidomide), CD38 monoclonal antibodies (daratumumab, isatuximab), SLAM7-targeted therapies (elotuzumab), and bispecific B-cell maturation antigen (BCMA)-targeted agents (teclistamab, elranatamab) [6]. The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.